BLAINJECTIONINJECTABLE
Approved
Aug 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
73
Data completeness
5/8 — Partial
REPATHA (evolocumab) by Amgen is pcsk9 inhibitors [moa]. Approved for pcsk9 inhibitor [epc]. First approved in 2015.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REPATHA (evolocumab) is a monoclonal antibody PCSK9 inhibitor that lowers LDL cholesterol by blocking the PCSK9 protein, allowing cells to remove more LDL from the blood. It is indicated for patients with hypercholesterolemia who require additional LDL-lowering therapy beyond statins. The drug is administered via subcutaneous injection.
Peak
REPATHA remains at peak commercial performance with established market presence; teams are focused on market maintenance and defending share against direct PCSK9 competitors.
Mechanism of Action
PCSK9 Inhibitors
Pharmacologic Class:
PCSK9 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (73)
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Started Jan 2027
308 enrolled
Coronary Artery DiseaseHypercholesterolemiaAtheroma+1 more
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
Started Dec 2026
44 enrolled
Abdominal Aortic Aneurysm
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Started Apr 2026
405 enrolled
Healthy Participants
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Started Apr 2026
5,995 enrolled
Cardiovascular DiseasesAtherosclerotic Cardiovascular DiseaseHypercholesterolemia, Familial
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Started Jan 2026
405 enrolled
Healthy ParticipantsPharmacokinetics
Worked on REPATHA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.